signal/raiseTrack rounds
SeedAI · San Diego

Tesorai raises $5.3m seed round to make raw life sciences lab data searchable

The San Diego company, started by former Verily staff, reprocesses data from thousands of published experiments. Backers include Perplexity Fund and IQT, and total funding is now $8m.

s/rFunding deskNorth America · 2 min read

Tesorai, a San Diego company that builds AI tools for life sciences research, said on 18 November 2026 that it had raised $5.3m in seed funding, bringing its total funding to $8m.

Investors in the round were Perplexity Fund, IQT, South Central Ventures, New Stack Ventures, NextGen Venture Partners, f7 Ventures, VitalStage Ventures and ZAKA. The company did not name a lead investor and did not disclose a valuation or headcount.

Tesorai raised a pre-seed round before this one, but did not give its size. SiliconANGLE also reported the seed round, with the same amount and investors.

“Every experiment produces far more data than its paper can report, and most of it is never revisited,”Melissa Miao, Co-founder and CEO, Tesorai

What Tesorai does

Biological experiments produce large raw data files, but published papers report only a small part of what those files contain. Data from millions of experiments sits in public repositories, institutional archives and company databases, processed in different ways and often poorly labelled. Tesorai's software goes back to the raw files, reanalyses them and puts results from different studies into a common form so researchers can search and compare them.

Its first focus is proteomics, the study of proteins, using data from mass spectrometry instruments. The platform has three parts: Tesorai Search, which processes raw data in the cloud; Tesorai Trove, a catalogue of thousands of curated public proteomics datasets; and Tesorai Chat, which lets researchers run analyses through a chat interface rather than relying on bioinformaticians.

To show what the approach can do, the company said its team reprocessed raw files from five public brain studies and found p-tau217, a leading marker of Alzheimer's disease that none of the original studies had reported. It posted that work as a preprint. In a separate preprint, its researchers reported that adding protein data allowed a small single-cell AI model to match or beat larger models trained only on RNA data, including one more than 40 times its size.

Who is behind it

The three co-founders worked together at Verily, Alphabet's life sciences company. Melissa Miao, the chief executive, led business initiatives and partnerships there; Charlie Kim, the chief scientific officer, started and led its molecular science programme; and Peter Cimermancic, the chief technology officer, led AI teams.

Since its pre-seed round, Tesorai said, it has signed contracts with biopharmaceutical and research organisations, worked with MD Anderson Cancer Center, New York University and the Michael J. Fox Foundation, and received its first US patent. Joanna Lee Shevelenko, a general partner at Perplexity Fund, said the impact of AI on science will depend on access to high-quality experimental data.

What the money is for

Tesorai said it would use the funding to expand its work with drug companies and research customers, build partnerships with companies that make life sciences tools, and extend the platform beyond proteins to other kinds of molecular data. It also plans to catalogue more public repositories and sell processed data to companies building AI models of biology.

The round comes as large organisations spend heavily on producing new biological data for AI. In October, Biohub, Google DeepMind, Meta, Isomorphic Labs and US agencies announced a $1.8bn effort to generate and standardise such data, according to the release. Tesorai presents its work as a complement that starts with data already collected. Researchers can try the platform without charge.

Company website: tesorai.com